Back to Journals » International Journal of Nanomedicine » Volume 9 » Issue 1

Transferrin-modified nanostructured lipid carriers as multifunctional nanomedicine for codelivery of DNA and doxorubicin

Authors Han Y, Zhang Y, Li D, Chen Y, Sun J, Kong F

Received 15 May 2014

Accepted for publication 20 June 2014

Published 25 August 2014 Volume 2014:9(1) Pages 4107—4116

DOI https://doi.org/10.2147/IJN.S67770

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3


Yiqun Han,1,† Ying Zhang,2,† Danni Li,3 Yuanyuan Chen,1 Jiping Sun,1 Fansheng Kong4

1Department of Respiratory Medicine, General Hospital of Ji’nan Command, PLA, 2Center of Interventional Therapy, Ji’nan Infectious Disease Hospital, 3Department of Internal Neurology, Ji’nan Central Hospital Affiliated to Shandong University, 4Department of Hematology, General Hospital of Ji’nan Command, PLA, Ji’nan, People’s Republic of China

These two authors contributed equally to this work

Background: Nanostructured lipid carriers (NLC), composed of solid and liquid lipids, and surfactants are potentially good colloidal drug carriers. The aim of this study was to develop surface-modified NLC as multifunctional nanomedicine for codelivery of enhanced green fluorescence protein plasmid (pEGFP) and doxorubicin (DOX).
Methods: Two different nanocarriers: pEGFP- and DOX-loaded NLC, and solid lipid nanoparticles (SLN) were prepared. Transferrin-containing ligands were used for the surface coating of the vectors. Their average size, zeta potential, and drug encapsulation capacity were evaluated. In vitro transfection efficiency of the modified vectors was evaluated in human alveolar adenocarcinoma cell line (A549 cells), and in vivo transfection efficiency of the modified vectors was evaluated in a mouse bearing A549 cells model.
Results: Transferrin-modified DOX and pEGFP coencapsulated NLC (T-NLC) has a particle size of 198 nm and a +19 mV surface charge. The in vitro cell viabilities of the T-NLC formulations were over 80% compared with the control. T-NLC displayed remarkably greater gene transfection efficiency and enhanced antitumor activity than DOX- and pEGFP-coencapsulated SLN in vivo.
Conclusion: The results demonstrate that T-NLC noticeably enhanced antitumor activity through the combination of gene therapy with chemotherapy. Also coating of active transferrin improved the lung cancer cell-targeting of the carriers. In summary, the novel gene and drug delivery system offers a promising strategy for the treatment of lung cancer.

Keywords: multifunctional delivery system, active targeting, transferrin modification, solid lipid nanoparticles
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]